Drug intelligence / Profile preview

LY3872386

Development stage: Discontinued
Lead developer: Eli Lilly
Administration: Intravenous, Subcutaneous

Overview

LY3872386 is an investigational drug that was developed by Eli Lilly for the treatment of atopic dermatitis. It is classified as an anti-inflammatory and skin disorder therapy, but its precise mechanism of action has not been defined in public sources. The drug was evaluated in phase 1 clinical trials to assess safety and tolerability in both healthy participants and those with atopic dermatitis. These studies included both intravenous and subcutaneous administration routes. As of July 2024, development was terminated based on emerging nonclinical data, and no further clinical advancement is planned.

Beyond the preview

Go deeper on LY3872386.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3872386.

Explore the full profile